Insmed Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Insmed Inc (INSM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Insmed Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,479M vs 31,674M combined for its competitors (4.5% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+41.8% annualized vs trailing 12 months), vs accelerating (+16.6%) for its tracked peer group.
- Growth: Insmed Inc generated 330.0% revenue growth year over year in Q3 2026, vs 8.0% for its competitors combined.
- Profitability: Its -19.1% net margin compares with 9.5% for the peer group.
- Scale: Insmed Inc ranks #24 of 546 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.4% of industry market cap.
- Peer revenue share: Insmed Inc accounted for 5.4% of combined revenue among its tracked peer group, up from 1.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.89M compares with $0.99M for the peer group (0.9x).
- Structure: Insmed Inc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
INSM Sales vs. its Competitors, Q3 2026
Insmed Inc reported revenue growth of 330.00 % year on year in Q3 2026, above its competitors' combined revenue growth of 7.99 %.
With a net margin of -19.13 %, Insmed Inc reported lower profitability than its competitors (9.53 %).
Insmed Inc generated 5.37 % of the combined sales of its peer group, up from 1.41 % a year earlier.
Insmed Inc vs. its Competitors, Q3 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Insmed Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Insmed Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Insmed Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Insmed Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 330.0% for Insmed Inc. Insmed Inc's share of combined industry revenue moved from 0.03% to 0.10%, a gain of 0.07 percentage points.
Insmed Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Insmed Inc | No | Yes | Yes | No |
| Competitors combined (49) | ||||
| High-Confidence Competitors (2) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
INSM Stock Performance relative to its Competitors
INSM Stock Performance relative to High-Confidence Competitors
INSM Stock Performance relative to Similar-Size Competitors
INSM Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 2 | Centessa Pharmaceuticals Plc | 282.9% | Outperformed |
| 3 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 4 | Puma Biotechnology Inc | 282.9% | Outperformed |
| 5 | Amicus Therapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Insmed Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Insmed Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Insmed Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Insmed Inc |
23,795.38 | 1,479.04 |
 Amgen Inc |
250,392.32 | 38,095.00 |
 Vertex Pharmaceuticals Inc |
138,446.00 | 12,951.60 |
 Teva Pharmaceutical Industries Limited |
49,425.74 | 14,020.00 |
 Viatris Inc |
22,067.80 | 14,737.30 |
 Biomarin Pharmaceutical Inc |
10,864.27 | 3,655.13 |
| SUBTOTAL | 549,796.69 | 92,867.05 |
Sign in to see all competitors of Insmed Inc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Insmed Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Insmed Inc's Competitors Named by the Company
Competitive relationships identified from Insmed Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Resilience | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Therapure Biopharma Inc. | Company report | 85% |
| PARI | Company report | 85% |
| Esteve | Company report | 85% |
| AstraZeneca | Company report | 85% |
| Optinose Inc | Company report | 85% |
| Ultragenyx Pharmaceutical Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Insmed Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Insmed Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Insmed Inc | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 57.61 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Insmed Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Insmed Inc | 23,795 | 888,846 | -363,948 |
| Amgen Inc | 250,392 | 2,930,385 | 672,538 |
| Vertex Pharmaceuticals Inc | 138,446 | 31,979,259 | 9,817,037 |
| Teva Pharmaceutical Industries Limited | 49,426 | 412,960 | 14,963 |
| Viatris Inc | 22,068 | 491,243 | -13,690 |
| Biomarin Pharmaceutical Inc | 10,864 | 1,134,780 | -5,934 |
| PEERS TOTAL | 526,001 | 988,919 | 107,929 |
Insmed Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Insmed Inc | United States 90.31 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Ultragenyx Pharmaceutical Inc | North America 52.02 % |
| Therapeuticsmd Inc | Non Us 66.30 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Insmed Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 496 companies in Insmed Inc's industry classification, broader than the peer set above. Market cap in millions of $.Insmed Inc ranks #24 of 496 companies by market capitalization in its industry, holding 0.39 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 896, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,913 | 21.47 % |
| 2 | Johnson and Johnson | 681,032 | 11.41 % |
| 3 | Beone Medicines Ltd | 589,304 | 9.88 % |
| 4 | Abbvie Inc | 528,644 | 8.86 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 24 | Insmed Inc | 23,517 | 0.39 % |
Market cap and industry share for the rest of Insmed Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-05.
Insmed Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 19 | Takeda Pharmaceutical Company Limited | 33,946 | 58.41 % |
| 20 | Spyre Therapeutics Inc | 33,037 | 315.45 % |
| 21 | United Therapeutics Corporation | 27,241 | 36.00 % |
| 22 | Roivant Sciences Ltd | 27,220 | 90.06 % |
| 23 | Zai Lab Limited | 1,234 | 12.3% |
| 24 | Insmed Inc | 23,517 | -40.80 % |
| 25 | Viatris Inc | 1,234 | 12.3% |
| 26 | Alnylam Pharmaceuticals Inc | 1,234 | 12.3% |
| 27 | Jazz Pharmaceuticals Plc | 1,234 | 12.3% |
| 28 | Ascendis Pharma A | 1,234 | 12.3% |
| 29 | Alterity Therapeutics Limited | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Insmed Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-05. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Insmed Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 83.97 % | 37.69 % (avg) | +46.3 pp |
| Operating Margin | -38.13 % | industry median | -49.4 pp |
| EBITDA Margin | -35.67 % | -6.49 % (avg) | -29.2 pp |
| Capital Intensity (Capex / Revenue) | 2.16 % | 7.58 % (avg) | -5.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Insmed Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 35.2x | 4.3x | +31.0x |
| Return on Equity | -82.75 % | industry aggregate | -116.93 % |
| Return on Invested Capital | -24.13 % | -9.93 % (avg) | -14.20 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Insmed Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | 20.48 % | 14.63 % | 29.38 % | 25.30 % | -8.83 % | 87.62 % |
| Operating Margin | - | -172.38 % | -161.32 % | -199.03 % | -187.56 % | - | - | - |
| Return on Invested Capital | -31.92 % | -25.79 % | -25.50 % | -25.92 % | -41.18 % | -81.80 % | -65.84 % | -50.27 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Insmed Inc's Strategic Group Map
Insmed Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Insmed Inc's trailing-12-month revenue growth of 332.3% and operating margin of -38.1% compares with an average of 310.7% growth and -8.2% margin across its 8 closest peers by combined growth, margin and ROIC -- Insmed Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Insmed Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Insmed Inc falls in the Dog quadrant: relative market share of 0.02x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Insmed Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 896 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.16 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Insmed Inc's dedicated Suppliers and Customers pages, not here.
Insmed Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Insmed Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Insmed Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+41.8% annualized vs trailing 12 months).
Weaknesses
- Operating margin 49.4 points below the industry median.
- Return on equity 116.9 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.02x).
Opportunities
- A meaningful share of competitors (51.10 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Insmed Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Insmed Inc | 0.94 | 3.11 | 0.75 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Teva Pharmaceutical Industries Limited | 0.26 | 0.96 | 2.09 |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
| Biomarin Pharmaceutical Inc | 1.07 | 3.41 | 0.47 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Insmed Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Insmed Inc | Q3 2026 | +330.0 % | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -1.9 % | -46.3 % |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| Biomarin Pharmaceutical Inc | Q3 2026 | +32.0 % | - |
| PEERS TOTAL | +13.0 % | +8.4 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Insmed Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Insmed Inc | Q3 2026 | +166.4 % | +132.6 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -10.2 % | +200.0 % |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
| Biomarin Pharmaceutical Inc | Q3 2026 | +46.6 % | -18.9 % |
Insmed Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Insmed Inc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Teva Pharmaceutical Industries Limited | 1.26% | 1.96% | 6.37% |
| Viatris Inc | - | - | - |
| Biomarin Pharmaceutical Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Insmed Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Insmed Inc | - | 16.09 |
| Amgen Inc | 28.59 | 6.57 |
| Vertex Pharmaceuticals Inc | 34.98 | 10.69 |
| Teva Pharmaceutical Industries Limited | 55.96 | 3.53 |
| Viatris Inc | - | 1.50 |
| Biomarin Pharmaceutical Inc | - | 2.97 |
| PEERS AVERAGE | 58.69 | 5.92 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.